PUBLICATIONS

 

Meeting Abstracts

2012

  1. Azimi A. et al. CHARACTERIZATION OF RESISTANCE MECHANISMS TO THE BRAF INHIBITOR VEMURAFENIB (PLX4032). WIN 2012 Symposium, Paris, June 28-29, 2012
  2. Azimi A. et al. CHARACTERIZATION OF RESISTANCE MECHANISMS TO THE BRAF INHIBITOR VEMURAFENIB (PLX4032). Oral presentation. Melanocytes and melanoma - from basic science to clinical applications, June 18-20, 2012.
  3. Azimi A., Hertzman Johansson C., Pernemalm M., Tuominen R., Lehtiö J. ,  Hansson J., Egyhazi, S. Proteomics approach to identify novel markers for response to therapy in cutaneos melanoma. Nordic melanoma meeting September 2012, oral presentation
  4. Bertolini G.,  Moro M. , Tortoreto M., Caserini R., Pastorino U., Roz L. and  Sozzi G. The subset of CD133+/CXCR4+/EpCAM- cancer initiating cells is responsible for lung tumor metastatic spreading. Poster session. EACR-22 biennial meeting. Barcelona 7-10 June 2012
  5. Egyházi S, Azimi A, Ghashghaei S, Frostvik Stolt M, Egyházi S, Hertzman Johansson C, Hansson J. Effects of combined exposure to BRAF and PI3K inhibitors with chemotherapeutic agents. WIN 2012 Symposium, Paris, June 28-29, 2012.
  6. Egyházi S, Azimi A, Ghashghaei S, Frostvik Stolt M, Egyházi S, Hertzman Johansson C, Hansson J. Effects of combined exposure to BRAF and PI3K inhibitors with chemotherapeutic agents. Melanocytes and melanoma - from basic science to clinical applications, June 18-20, 2012.
  7. Hasmats, J. and Green H. Using whole exome sequencing to identify genetic candidates for carboplatin and gemcitabine induced toxicities. WIN 2012 Symposium, Paris, June 28-29, 2012.
  8. Hertzman Johansson C, A. Azimi , M. Pernemalm , Y. Pawitan , M. Frostvik Stolt , V. Lazar , J. Lundeberg , J. Lehtiö , S. Egyhazi , J. Hansson PROTEOMICS AND GENE EXPRESSION PROFILING OF MELANOMA CHEMOTHERAPY RESPONSE IN TUMORS. WIN 2012 Symposium, Paris, June 28-29, 2012.
  9. Hertzman Johansson C, A. Azimi , M. Pernemalm , Y. Pawitan , M. Frostvik Stolt , V. Lazar , J. Lundeberg , J. Lehtiö , S. Egyhazi , J. Hansson PROTEOMICS AND GENE EXPRESSION PROFILING OF MELANOMA CHEMOTHERAPY RESPONSE IN TUMORS. Oral presentation. Melanocytes and melanoma - from basic science to clinical applications, June 18-20, 2012.
  10. Jakobsen Falk I.A., K.H.Z. Gréen, K. Lotfi, A. Fyrberg. CORRELATION BETWEEN CYTIDINE DEAMINASE SINGLE NUCLEOTIDE POLYMORPHISMS AND DNA METHYLATION IN ACUTE MYELOGENOUS LEUKEMIA. WIN 2012 Symposium, Paris, June 28-29, 2012.
  11. Pernemalm  M, Branca R, De Petris L, Forshed J, Lewensohn R, Besse B, Lazar V, Van den Oord J, Pawitan Y, Lehtiö J. Proteomics anchored systems biology analysis of prognostic factors in primary lung adenocarcinoma tumours. WIN 2012 Symposium, Paris, June 28-29, 2012.
  12. Planchard D, B. Lueza, A. Rahal, L. Lacroix, M. Ngocamus, N. Auger, P. Saulnier, P. Dorfmuller, T. Le Chevalier, A. Celebi, J.P. Pignon, J.C. Soria, B. Besse. UPFRONT GENOMIC TESTING FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER RECEIVING FIRST-LINE PLATINUM-BASED REGIMEN: PRELIMINARY RESULT OF THE MSN STUDY. WIN 2012 Symposium, Paris, June 28-29, 2012.

2011

  1. Akbar, N., Salim, H., Zong, D, Viktorsson, K., Moshfegh, A., Lewensohn, R. and Zhivotovsky, B. (2011). miR-214 overexpression protects NSCLC against radiotherapy-induced cell death by causing impaired apoptotic signalling. International Association for the Study of Lung Cancer (ISLAC): 14th World Conference on Lung Cancer 3-7 July 2011, Amsterdam, The Netherlands.
  2. Azimi, A., Hertzman Johansson C., Hansson J., Egyhazi, S. In vitro study of and targeted therapies and resistance mechanisms in melanoma. Nordic melanoma meeting, September 2011, oral presentation.
  3. Azimi A., Hertzman Johansson C., Pernemalm M., Tuominen R., Lehtiö J. ,  Hansson J., Egyhazi, S. Targeted therapies in melanoma - in vitro effects of single and combined drug treatment AACR 102 annual meeting 6-9 November 2011, Poster presentation
  4. Bertolini G., L. Roz, M. Tortoreto, M. Boeri, U.Pastorino, G. Sozzi. Epithelial-mesenchymal transition confers stem-like properties and migratory ability to lung tumor cells. Poster session. AACR Annual Meeting 2011. Orlando, FL. April  2-6 2011
  5. Bertolini G., Roato I., Moro M., Caserini R., Tortoreto M., Pastorino U. , Roz L., Ferracini R., Sozzi G. The subpopulation of CD133+/CXCR4+ lung tumor initiating cells are endowed with an highly metastatic potential. Oral communication. 53nd Annual Meeting of the Italian Cancer Society. Turin 9-11 October 2011
  6. Dali Zong, Petra Hååg, Rolf Lewensohn and Kristina Viktorsson. Inhibition of DNA Repair by Trifluoperazine Sensitizes Human Lung Cancer Cells to Apoptosis Associated with Lysosomal Dysfunction Following Prolonged G2-M Checkpoint Arrests. AACR, April 2-6 Orlando 2011.
  7. De Petris, L & Lewensohn, R. (2011) Systemsbiology in lung cancer and discovery of novel biomarkers. Speaker: L. De Petris. Swedish Lung Cancer Research in Focus. Research seminar organized by the Swedish Planning group for Lung Cancer & Roche AB Sweden, Stockholm, 25th of September, 2011.
  8. Efazat, G*., Haag, P*., Zong, D., Stenke, L., Sunnerhagen, P., Nilsson, A., Viktorsson, K and Lewensohn, R. Ghazal Efazat, Petra Haag, Dali Zong, Leif Stenke, Per Sunnerhagen, Anders Nilsson, Kristina Viktorsson and Rolf Lewensohn (2011) The DNA glycosylase Myh1 is stabilized by cisplatin and inhibition of Myh1 expression increases cisplatin-induced apoptotic signaling in lung carcinoma cells. 4th European course of in vivo preclinical assays in cancer therapy. Paris, France, May 18-20, 2011.
  9. Efazat, G., Stahl, S., Kaminsky, V., Selck, C., Haag, P., Lewensohn, R., Zhivotovsky, B., Viktorsson, K. (2011).Role of an EphA2/Ephrin B3 signalling circuit in regulation of NSCLC response to radiotherapy. International Association for the Study of Lung Cancer (ISLAC): 14th World Conference on Lung Cancer 3-7 July, 2011, Amsterdam, The Netherlands.
  10. Efazat, G., Stahl, S., Kaminsky, V., Selck, C., Haag, P., Lewensohn, R., Zhivotovsky, B., Viktorsson, K. (2011). An EphA2/Ephrin B3 signaling circuit regulates radiotherapy responsiveness of Non small cell lung carcinoma. Hallmarks &Horizons of Cancer, ISREC Symposium 7-11 September, 2011, Lausanne, Switzerland
  11. Efazat, G., Stahl, S., Kaminsky, V., Selck, C., Haag, P., Lewensohn, R., Zhivotovsky, B., Viktorsson, K. (2011).An EphA2/Ephrin B3 signaling circuit regulates radiotherapy responsiveness of Non small cell lung carcinoma. KICancer Retreat. September 29-30, 2011, Stockholm, Sweden.
  12. Efazat, G., Stahl, S., Kaminsky, V., Selck, C., Haag, P., Lewensohn, R., Zhivotovsky, B., Viktorsson, K. (2011).An EphA2/Ephrin B3 signaling circuit regulates radiotherapy responsiveness of Non small cell lung carcinoma. Oncological Nuclide Therapy. November 16-18, 2011.Uppsala, Sweden
  13. Hogir Salim, Lovisa Lundholm, Dali Zong, Petra Hååg, Kristina Viktorsson and Rolf Lewensohn. mRNA and miRNA profiling of platinum-resistant non-small cell lung cancer clones identifying potential targets involved in DNA metabolism and DNA replication. AACR, April 2-6 Orlando 2011.
  14. Lehtiö J., Comprehensive Cancer Proteomics; from low resolution picture to details, Invited talk, ESMO-ECCO, the European Multidisciplinary Cancer Congress, Stockholm Sep 2011.
  15. Lehtiö J., Comprehensive human proteomics by high resolution peptide isoelectric focusing prefractionation and mass spectrometry (hrIEF-LC-MS/MS), Invited talk, The 2nd Polish Congress of Biochemistry and Cell Biology, Krakow, Poland, Sep 2011
  16. Lewensohn R. Overview of 50 year stereotactic radiosurgery and SBRT. ESTRO Pre-meeting course on Radiosurgery and Stereotactic Body Radiation. 8 May 2011, London, UK.
  17. Lewensohn R. Stereotactic Radiotherapy. European Society of Thoracic Surgeons, ESTS, 19th European Conference on general thoracic surgery. 8 June 2011, Marseille, France.
  18. Lewensohn, R & Viktorsson, K ,(2011) Role of Ephrin & Ephrin receptors in sensitivity to radiotherapy and drugs. Speaker: R. Lewensohn. ETOP Meeting, Netherlands Cancer Institute, Amsterdam, The Netherlands, 11th of November 2011.
  19. Perego M et al. Melanoma cells with stemness features and their interaction with cytokine network. Seminar at Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania 19104, Molecular and Cellular Oncogenesis Program directed by M.Helryn,  7th November 2011
  20. Perego M., A. Tuccitto, M. Tazzari, V. Beretta, F. Rini, L. Rivoltini, C. Castelli. In?uence of immune related factors in the modulation of melanoma stemness. 2011 International Melanoma Congress of the Society for Melanoma Research, 9-13 November, 2011 Tampa
  21. Salim, H, Akbar, N.S. Viktorsson, K., Lewensohn, R., Moshfegh, A. and Zhivotovsky, B.(2011). microRNA profiling in small and non-small cell carcinomas with different response to radio- and chemotherapy. Frontiers in cancer research and therapy, March 8-9, 2011, Nobel Forum, Karolinska, Stockholm, Sweden.
  22. Salim, H., Akbar, N., Zong, D., Moshfegh, A., Viktorsson, K., Lewensohn, R., Zhivotovsky, B. (2011). Down regulation of miR-214 sensitizes NSCLC cells to ionizing radiation by increasing the senescence signalling. International Association for the Study of Lung Cancer (ISLAC): 14th World Conference on Lung Cancer 3-7 July, 2011, Amsterdam, The Netherlands.
  23. Salim, H., Lundholm,L.,  Zong, D., Haag, P., Viktorsson, K., and Lewensohn, R., (2011) mRNA and miRNA profiling of platinum-resistant non-small cell lung cancer clones identifying potential targets involved in DNA metabolism and DNA replication. American Association for Cancer Research, Orlando, USA, April 2011. 
  24. Viktorsson, K & Lewensohn, R (2011). A role of Ephrin and Eph signaling circuits in Lung Cancer therapy sensitivity. Speaker: K. Viktorsson. Swedish Lung Cancer Research in Focus. Research seminar organized by the Swedish Planning group for Lung Cancer & Roche AB Sweden, Stockholm, 25th of September, 2011.
  25. Zong, D., Haag, P., Lewensohn, R and Viktorsson, K (2011) Impairment of γH2AX Resolution by Trifluoperazine Causes Delayed Escape from G2-M Checkpoint Arrests and Apoptosis Associated with Oxidative Stress and Lysosomal Dysfunction. American Association for Cancer Research, Orlando, USA, April 2011.

 2010

  1. Bertolini G., Roz L., Boeri M., Sozzi G. “Epithelial-mesenchymal transition confers stem-like properties to lung tumor cells” (52nd Annual Meeting of the Italian Cancer Society. Rome 4-7 October 2010).
  2. Bertolini G., Roz L., Caserini R., Perego P., Gatti L., Tortoreto M., Andriani F., Roz E., Pastorino U., Sozzi G. “Tumorgrafts as a novel pre-clinical model to study the chemoresistance of lung cancer stem cells” (Targeting Cancer stem cells Boston, MA, USA. March 24-25 2010).
  3. Björnstad K, J, Johansson H, Lengqvist, Lehtiö J. (2010). Analysis of S100 proteins in A549 cell lysate using peptide isoelectric focusing and selected reaction monitoring (SRM). 14th Nordic MS Conference, August 2010.
  4. Chiara Castelli. Chair of the Session I: Immunobiology of cancer stem cells VIII NIBIT Meeting, Certosa di Pontignano, Siena, Italy.
  5. Gatti L., Cossa G., Bertolini G., Tortoreto M., Tinelli S., Fontanella E., Delia D., Roz L., Sozzi G. and Perego P. “Increased expression of ABC transporter genes in lung cancer CD133 positive cells” (ATP-Binding Cassette Proteins: From Multidrug Resistance to Genetic Disease 3rd FEBS Special Meeting, Innsbruck, Austria, 2010).
  6. K. Viktorsson, G. Efazat, P. Haag, D. Zong, L. Stenke, P. Sunnerhagen, R. Lewensohn. The DNA glycosylase Myh1 is stabilized by cisplatin and inhibition of Myh1 expression increases cisplatin-induced apoptotic signaling in lung carcinoma cells. EJC Supplements June 2010 (Vol. 8, Issue 5, Pages 134-135).
  7. Lehtiö J (2010). Critical Issues in Lung Cancer Research”: Lung Cancer Omics Research - The Swedish Perspective”. Invited speaker on The swedish cancer society conference "Critical issues in Lung Cancer research", February, 2010.
  8. Lundholm, L., D. Zong, P. Hååg, H. Salim, R. Lewensohn, K. Viktorsson. miRNA and cancer stem cell analysis of NSCLC to explain the sensitizing effect of trifluoperazine on cisplatin-induced cell death signaling. EJC Supplements June 2010 (Vol. 8, Issue 5, Page 113)
  9. Michela Perego. Immunological aspects of melanoma cancer stem cells, VIII NIBIT Meeting, Certosa di Pontignano, Siena, Italy.
  10. S.Stahl, A. Vaculova, V. Kaminskyy, S. Rodriguez-Nieto, A. Moshfegh, R. Lewensohn, K. Viktorsson, B. Zhivotovsky. Global gene analysis reveals ephrin B3 as a potential radio sensitizing target in non small cell lung cancer cells. EJC Supplements. June 2010 (Vol. 8, Issue 5, Page 134).
  11. Salim, H., Akbar, N.S., Viktorsson, K., Lewensohn, R., Moshfegh, A and Zhivotovsky, B. MicroRNA profiling in small and non-small cell lung Carcinomas with different response to radio- and chemotherapy. 18th Euroconference on Apoptosis, September 1-4, 2010, Ghent, Belgium.
  12. Viktorsson K. (2010). Critical Issues in Lung Cancer Research”: Pathways for Therapy Sensitivity & Resistance in Lung Cancer - The Swedish Perspective”. Invited speaker on The swedish cancer society conference "Critical issues in Lung Cancer research", February, 2010.
  13. Viktorsson, K. (2010). Discovery of new targets for radiotherapy using a systemsbiology approach. Djurönäset, August, 2010.

 

2009

  1. G. Bertolini, L. Roz, P. Perego, L. Gatti, M. Tortoreto, F. Andriani, E. Roz, S. Lo Vullo, D.Delia, U. Pastorino, G. Sozzi. “Highly tumorigenic lung cancer CD133-positive cells display stem-like features and are spared by cisplatin treatment” (51° Annual Meeting of the Italian Cancer Society, Sesto S. Giovanni, Italy 2009)
  2. Gatti L., Cossa G., Bertolini G., Tortoreto M., Tinelli S., Fontanella E., Delia D.,.Roz L., Sozzi G. and Perego P. “Increased expression of ABC transporter genes in lung cancer CD133 positive cells” (AACR-NCI-EORTC International Conference “Molecular Target and Cancer Therapeutics”, Boston, USA, 2009)
  3. Gatti L., Cossa G., Bertolini G., Tortoreto M., Tinelli S., Roz L., Sozzi G. and Perego P. “Increased expression of ABC transporter genes in lung cancer CD133 positive cells” (51° Annual Meeting of the Italian Cancer Society, Sesto S. Giovanni, 2009)
  4. Giulia Bertolini, Luca Roz, Paola Perego, Graziella Pratesi, Francesca Andriani, Elena Roz, Salvatore Lo Vullo, Domenico Delia, Ugo Pastorino, Gabriella Sozzi. “Highly tumorigenic lung cancer CD133-positive cells display stem-like features and are spared by cisplatin treatment” (51° AACR Annual Meeting 2009, Denver, USA 2009 )
  5. Johansson C, Tuominen R, von Gertten C, Wiberg H, Grafström E, Lindberg J, Lundeberg J, Hansson J, Egyhazi S. The potential role of melanosomes and transport proteins in melanoma chemotherapy resistance.7th World Congress on Melanoma and 5th Congress of the EADO, Vienna, May 12-15, 2009.
  6. Lindberg J, Grafstrom E, Frostvik Stolt M, Hansson J, Lundeberg J, Egyhazi S. Gene expression profiles in metastatic cutaneous melanoma with differential response to chemotherapy. 7th World Congress on Melanoma and 5th Congress of the EADO, Vienna, May 12-15, 2009.
  7. Rottenberg et al.: Modeling chemotherapy resistance - insights from a mouse model for hereditary breast cancer. AACR Mouse Models of Cancer, San Francisco, USA, January 12-15, 2009
  8. Wickström M., Viktorsson K., Lundholm L., Aesoy R., Nygren H, Sooman L., Fryknäs M., Lewensohn R., Larsson R., Gullbo J. Role of aminopeptidase n in the activation of the alkylating prodrug j1. Abstract in supplementary to Molecular Cancer therapeutics, Dec. issue, 2009.
  9. Zander et al.: ABCG2/BCRP1-deficient spontaneous mammary tumors show a delay in acquiring topotecan resistance, but cannot be eradicated. AACR Mouse Models of Cancer, San Francisco, USA, January 12-15, 2009

 

2008

  1. Castelli C et al, Cells with cancer stem cells properties can be isolated from human melanoma 6th NIBIT Annual Meeting. October 16-18, 2008, Certosa di Pontignano, Siena, Italy.
  2. Giulia Bertolini, Graziella Pratesi, Luca Roz, Anna Livio, Monica Tortoreto, Alessandra Fabbri , Enrico Fontanella, Francesca Andriani, Delia Domenico, Ugo Pastorino, Gabriella Sozzi. Identification of human lung tumor initiating cells. July 9-12, 2008 Liverpool, UK.
  3. Lehtiö J., Lengqvist J., Orre L., Eriksson H., Persson B., Jacobsson P.J., Lewensohn R. Use of IEF-LC-MS/MS reveals proteome components involved in lung cancer therapy response MCP supplement (HUPO 7th Annual World Congress, Aug 2008: poster P-tue-072)
  4. Lengqvist J., Orre L. and Lehtiö J. Building a repository of validated MRM-transitions for targeted pathway biology. MCP supplement (HUPO 7th Annual World Congress, Aug 2008: poster P-mon-303)
  5. Mortarini R., Casà V., Zanon M., Baldassari P., Zaffaroni N., Daidone MG., Anichini A. Modulation of melanoma resistance to apoptosis by inhibition of IAP proteins expression. 50° Congresso Nazionale della Società Italiana di Cancerologia. Napoli 6-9/10/2008.
  6. Perego M et al, Cells with cancer stem cells properties can be isolated from human melanoma, AACR Special Conference in Cancer Research: The role of Cancer Stem Cells in the Initiation and Propagation of Tumorigenesis. February 12-15, 2008, Los Angeles, CA, USA.
  7. Rottenberg et al.: A low expression of Abcb1a and Abcb1b induces chemotherapy resistance in a realistic mouse model for human hereditary breast cancer. ABC transporter meeting in Innsbruck, Austria, March 1-6, 2008.
  8. Vallacchi V et al. CCN3 promotes melanoma progression by regulating integrin expression, adhesion and chemoresistance The 5th International Workshop on the CCN Family of Genes – Toronto, Canada, October 18th-20th, 2008.
  9. Zander et al.: ABCG2/BCRP1-deficient spontaneous mammary tumors show a delay in acquiring topotecan resistance. ABC transporter meeting in Innsbruck, Austria,  March1-6, 2008.
  10. Zong, D., Hååg, P. Yakymovych, I. Stenke, L. Lewensohn, R. and Viktorsson, K.  Inhibition of DNA double strand repair by Trifluoperazine mediates chemosensitization through enhanced activation of stress-induced mitochondrial apoptotic pathway Annual Symposium DNA damage: from causes to cures, Cambridge, England, 15-18 December 2008.

 

2007

  1. Bertolini G, Pratesi G, Roz L, Livio A, Tortoreto M, Fabbri A, Fontanella E, Andriani F, Delia D, Pastorino U, Sozzi G. Identification of human lung tumor initiating cells. International Workshop on cancer Stem Cells.  December 1-3, 2007, IFOM-IEO Campus, Milan, Italy.
  2. Bouwhuis M, Suciu S, Kruit W, Salès F, Patel P, Punt C, Stoitchkov K, Delaunay M, ten Hagen T, Eggermont AM, EORTC Melanoma Group. Prognostic value of autoantibodies (auto-AB) in melanoma patients (pts) in the EORTC 18952 trial of adjuvant interferon (IFN) vs observation (Obs). Proc ASCO 43rd Annual Meeting, 2007;25:Abstract 8507.
  3. Bouwhuis M, Suciu S, Testori A, Santinami M, Kruit W, Punt C, Salès F, Patel P, Spatz A, Eggermont AMM. Prognostic value of autoantibodies (auto-AB) in melanoma stage III patients in the EORTC 18991 phase III randomized trial comparing adjuvant pegylated interferon α2b (PEG-IFN) vs Observation. Eur J Cancer - Supplements 2007;5(6):11: abstract 3BA.
  4. Gasparini P, Bertolini G, Magnifico A, Casarsa C, Finocchiaro G, Daidone MG, Menard S, Sozzi G. Molecular cytogenetic characterization of tumor iniziating cells. International Workshop on cancer Stem Cells.  December 1-3, 2007, IFOM-IEO Campus, Milan, Italy
  5. Perego M, Deho P, Pratesi G, Tortoreto M, Daidone MG, Binda M, Patuzzo R, Santinami M, Tragni G, Castelli C. Cells with cancer stem cells can be isolated from human melanoma. SIC meeting: “VII Meeting of molecular oncology” May 14-17, 2007 Positano, Italy.
  6. Perego M, Deho P, Pratesi G, Tortoreto M, Daidone MG, Binda M, Patuzzo R, Santinami M, Tragni G,  Parmiani G,  Castelli C. Cells with cancer stem cell properties can be isolated from human melanoma Facoltà di Medicina e Chirurgia: “Circulating tumor cells, chemokines and cancer stem cells” 18 Settembre 2007,  Università Degli Studi di  Brescia, Brescia, Italy.

 

Page updated by Chemores October 26, 2012
Print info: http://mediabyran.kib.ki.se/publications/abstracts/index.html - Sunday, 20-Aug-2017 02:04:20 CEST
Producerad av Mediabyrån